These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26339916)

  • 1. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
    Vízkeleti L
    Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of CCND1 alterations during the progression of cutaneous malignant melanoma.
    Vízkeleti L; Ecsedi S; Rákosy Z; Orosz A; Lázár V; Emri G; Koroknai V; Kiss T; Ádány R; Balázs M
    Tumour Biol; 2012 Dec; 33(6):2189-99. PubMed ID: 23001925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.
    Lázár V; Ecsedi S; Szöllosi AG; Tóth R; Vízkeleti L; Rákosy Z; Bégány A; Adány R; Balázs M
    Mod Pathol; 2009 Oct; 22(10):1367-78. PubMed ID: 19633643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
    Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
    Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of the expressions of CAV1 and TES genes on 7q31 in melanoma.
    Vizkeleti L; Ecsedi S; Rakosy Z; Begany A; Emri G; Toth R; Orosz A; Szollosi AG; Mehes G; Adany R; Balazs M
    Front Biosci (Elite Ed); 2012 Jan; 4(5):1802-12. PubMed ID: 22201996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varying Mutational Alterations in Multiple Primary Melanomas.
    Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
    J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.
    Puig-Butillé JA; Badenas C; Ogbah Z; Carrera C; Aguilera P; Malvehy J; Puig S
    Exp Dermatol; 2013 Feb; 22(2):148-50. PubMed ID: 23362874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
    Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
    Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas: An Analysis With Newly Found Molecular Alterations and Some Population-Based Molecular Differences.
    Wroblewska JP; Mull J; Wu CL; Fujimoto M; Ogawa T; Marszalek A; Hoang MP
    Am J Surg Pathol; 2019 Feb; 43(2):168-177. PubMed ID: 30273197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.